We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comment on: "Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. Gastric cancer, 2021 Aug 11" by Iwatsuki et al.
- Authors
Ding, Yongfeng; Jiang, Junjie; Xu, Nong
- Abstract
10.1200/JCO.2015.63.7215 4 Zhao Y, Zhang J, Yang D, Tang Z, Wang Q. Feasibility of laparoscopic total gastrectomy for advanced Siewert type II and type III esophagogastric junction carcinoma: a propensity score-matched case-control study. In addition, for patients with advanced Siewert type II and type III EGJC, a propensity score-matched case-control study presented that the anastomotic leakage rates for the laparoscopic total gastrectomy and open total gastrectomy groups were 4.5 and 3.7%, respectively [[4]]. Despite a high 3 year OS and RFS rate for LAGC and EGJC observed in this single-arm phase II study, it is still unknown whether those patients benefit more from perioperative SOX regimen or standard postoperative chemotherapy.
- Subjects
ESOPHAGOGASTRIC junction; NEOADJUVANT chemotherapy; STOMACH cancer; ESOPHAGOGASTRIC junction cancer; OXALIPLATIN; LYMPHADENECTOMY; CHEMORADIOTHERAPY
- Publication
Gastric Cancer, 2021, Vol 24, Issue 6, p1376
- ISSN
1436-3291
- Publication type
Article
- DOI
10.1007/s10120-021-01247-9